Neuphoria Therapeutics (NEUP) vs. Its Peers Financial Contrast

Neuphoria Therapeutics (NASDAQ:NEUP) is one of 618 public companies in the “MED – BIOMED/GENE” industry, but how does it contrast to its peers? We will compare Neuphoria Therapeutics to related businesses based on the strength of its earnings, dividends, institutional ownership, valuation, risk, profitability and analyst recommendations.

Profitability

This table compares Neuphoria Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Neuphoria Therapeutics	N/A	-1.95%	-1.47%
Neuphoria Therapeutics Competitors	-1,366.22%	-644.69%	-28.50%

Earnings and Valuation

This table compares Neuphoria Therapeutics and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Neuphoria Therapeutics	$15.65 million	-$370,000.00	0.92
Neuphoria Therapeutics Competitors	$971.27 million	-$44.00 million	11.79

Neuphoria Therapeutics’ peers have higher revenue, but lower earnings than Neuphoria Therapeutics. Neuphoria Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Neuphoria Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Neuphoria Therapeutics’ peers have a beta of 0.97, indicating that their average stock price is 3% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Neuphoria Therapeutics and its peers, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuphoria Therapeutics	1	0	2	0	2.33
Neuphoria Therapeutics Competitors	5461	12030	37384	1135	2.61

Neuphoria Therapeutics currently has a consensus target price of $28.00, indicating a potential upside of 472.60%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 60.86%. Given Neuphoria Therapeutics’ higher probable upside, equities analysts clearly believe Neuphoria Therapeutics is more favorable than its peers.

Institutional & Insider Ownership

15.9% of Neuphoria Therapeutics shares are owned by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are owned by institutional investors. 1.5% of Neuphoria Therapeutics shares are owned by insiders. Comparatively, 13.6% of shares of all “MED – BIOMED/GENE” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Neuphoria Therapeutics peers beat Neuphoria Therapeutics on 8 of the 13 factors compared.

About Neuphoria Therapeutics

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.